Milestone Pharmaceuticals Stock News

Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Milestone Pharmaceuticals Inc.

MONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S.

MONTREAL and CHARLOTTE, N.C., Nov. 21, 2023 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a fireside chat at

Today, we take a deeper look at Milestone Pharmaceuticals Inc. for the first time on Seeking Alpha. The company's primary drug candidate has a novel delivery system and should have an NDA submitted ar

Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall

Analysts say these are penny stocks to buy. Do you agree?

Etripamil succeeded in phase 3 RAPID study, Milestone in talks with FDA to possibly file an NDA for this drug in treating PSVT patients by mid-2023. It is said that there are about 2 million PSVT pati

Milestone Pharmaceuticals reported positive data from the RAPID arm of its pivotal trial. After an initial premarket spurt, the stock dropped drastically.

Milestone Pharmaceuticals (MIST) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea

Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to imp

ABVC BioPharma (OTCMKTS:ABVC) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk. Volatility & Risk ABVC BioPharma has a beta of 0.55, indicating that its stock price […]

Renaissance Technologies LLC trimmed its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 50.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 107,554 shares of the companys stock after selling 108,846 shares during the period. Renaissance Technologies LLC owned about 0.36% of Milestone []

Zacks Investment Research upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a sell rating to a hold rating in a research note published on Thursday morning, Zacks.com reports. According to Zacks, Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular []